Vascular Biogenics Company Profile (NASDAQ:VBLT)

About Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VBLT
  • CUSIP: N/A
  • Web: www.vblrx.com
Capitalization:
  • Market Cap: $162.05 million
  • Outstanding Shares: 27,009,000
Average Prices:
  • 50 Day Moving Avg: $5.78
  • 200 Day Moving Avg: $5.22
  • 52 Week Range: $3.90 - $7.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.69
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.30 per share
  • Price / Book: 4.62
Profitability:
  • EBITDA: ($18,320,000.00)
  • Return on Equity: -44.15%
  • Return on Assets: -39.46%
Debt:
  • Current Ratio: 6.48%
  • Quick Ratio: 6.48%
Misc:
  • Average Volume: 157,900 shs.
  • Beta: -3.09
  • Short Ratio: 2.48
 

Frequently Asked Questions for Vascular Biogenics (NASDAQ:VBLT)

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.01. View Vascular Biogenics' Earnings History.

When will Vascular Biogenics make its next earnings announcement?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Vascular Biogenics.

Where is Vascular Biogenics' stock going? Where will Vascular Biogenics' stock price be in 2017?

4 brokerages have issued 12-month price targets for Vascular Biogenics' shares. Their predictions range from $11.00 to $20.00. On average, they anticipate Vascular Biogenics' stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Vascular Biogenics.

What are analysts saying about Vascular Biogenics stock?

Here are some recent quotes from research analysts about Vascular Biogenics stock:

  • 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (10/18/2017)
  • 2. Piper Jaffray Companies analysts commented, "At the previous Nov '16 update, the study achieved its primary endpoint of 6-month PFS at therapeutic doses, as well as an intriguing overall survival benefit. However, today's update demonstrates a PFS-6 benefit of 47% vs 25% for therapeutic versus sub-therapeutic doses of VB-111, and confirmed a survival benefit, with mOS at 684 days in the therapeutic cohort. We see these results as meaningful in patients who had progressed on prior therapies including TKi's, and the safety and efficacy profile in this third tumor type reduces risk for VB-111 and the broader platform. That said, we don't expect VBL to pursue a Phase IIb/III trial in thyroid at this time, in favor of focusing on ongoing rGBM and soon-to-be-initiated ovarian cancer studies. In advance of clinical updates from those during 2017, we reiterate OW." (2/21/2017)

Who are some of Vascular Biogenics' key competitors?

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:

  • Dror Harats M.D., Chief Executive Officer, Founder, Director
  • Amos Ron, Chief Financial Officer
  • Jacob George M.D., Chief Scientific Officer
  • Eyal Breitbart Ph.D., Vice President - Research and Operations
  • Erez Feige, Vice President - Business Operations
  • Yael Cohen M.D., Vice President - Clinical Development
  • Naamit Sher Ph.D., Vice President - Drug Development and Regulatory Affairs
  • Ayelet Horn, General Counsel, Company Secretary
  • Bennett M. Shapiro M.D., Non-Executive Independent Chairman of the Board
  • Ruth Alon, Non-Executive Director, Independent Director

How do I buy Vascular Biogenics stock?

Shares of Vascular Biogenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of Vascular Biogenics stock can currently be purchased for approximately $6.00.


MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vascular Biogenics (NASDAQ:VBLT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.75 (145.83% upside)
Consensus Price Target History for Vascular Biogenics (NASDAQ:VBLT)
Price Target History for Vascular Biogenics (NASDAQ:VBLT)
Analysts' Ratings History for Vascular Biogenics (NASDAQ:VBLT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2017HC WainwrightReiterated RatingBuy$11.00LowView Rating Details
2/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$11.00N/AView Rating Details
12/1/2016Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
11/29/2016Chardan CapitalSet Price TargetBuy$20.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00N/AView Rating Details
11/13/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Vascular Biogenics (NASDAQ:VBLT)
Earnings by Quarter for Vascular Biogenics (NASDAQ:VBLT)
Earnings History by Quarter for Vascular Biogenics (NASDAQ VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.21)N/AView Earnings Details
8/14/20176/30/2017($0.19)($0.18)ViewN/AView Earnings Details
5/15/20173/31/2017($0.17)($0.19)ViewN/AView Earnings Details
3/27/201712/31/2016($0.19)($0.18)ViewListenView Earnings Details
11/10/2016Q316($0.15)($0.12)ViewN/AView Earnings Details
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Biogenics (NASDAQ:VBLT)
Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.78 EPS

Dividends

Dividend History for Vascular Biogenics (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ:VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Vascular Biogenics (NASDAQ:VBLT)
Latest Headlines for Vascular Biogenics (NASDAQ:VBLT)
Source:
DateHeadline
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 4:42 PM
finance.yahoo.com logoVBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
finance.yahoo.com - October 3 at 2:26 PM
finance.yahoo.com logoVBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
finance.yahoo.com - October 3 at 2:26 PM
nasdaq.com logoVBL Therapeutics to Present at the Chardan Gene Therapy Conference
www.nasdaq.com - September 28 at 8:54 AM
americanbankingnews.com logoVascular Biogenics (VBLT) versus Its Competitors Head to Head Analysis
www.americanbankingnews.com - September 27 at 4:32 PM
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 4:36 PM
finance.yahoo.com logoVBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New York
finance.yahoo.com - September 15 at 10:59 AM
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - September 10 at 6:34 AM
finance.yahoo.com logoVBL Therapeutics to Present at the Rodman & Renshaw Global Investment Conference in New York on September 10-12, 2017
finance.yahoo.com - August 29 at 9:19 AM
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:36 PM
finance.yahoo.com logoStrength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%
finance.yahoo.com - August 17 at 8:59 AM
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) PT Set at $11.00 by HC Wainwright
www.americanbankingnews.com - August 15 at 6:40 PM
seekingalpha.com logoVascular Biogenics' (VBLT) CEO Dror Harats on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 15 at 3:36 PM
finance.yahoo.com logoEdited Transcript of VBLT earnings conference call or presentation 14-Aug-17 12:30pm GMT
finance.yahoo.com - August 15 at 3:35 PM
americanbankingnews.com logoVascular Biogenics Ltd. (NASDAQ:VBLT) Posts Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - August 14 at 11:30 AM
benzinga.com logoEarnings Scheduled For August 14, 2017 - Benzinga
www.benzinga.com - August 14 at 8:11 AM
finance.yahoo.com logoVBL Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 8:11 AM
finance.yahoo.com logoVascular Biogenics reports 2Q loss
finance.yahoo.com - August 14 at 8:11 AM
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 7 at 7:08 AM
americanbankingnews.com logoHead to Head Review: Vascular Biogenics (VBLT) vs. MEI Pharma (MEIP)
www.americanbankingnews.com - August 4 at 10:16 PM
finance.yahoo.com logoVBL Therapeutics to Report Second Quarter 2017 Results on August 14
finance.yahoo.com - August 2 at 8:23 AM
americanbankingnews.com logoVascular Biogenics Ltd. (NASDAQ:VBLT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 28 at 4:39 PM
thestreet.com logoVascular Biogenics is Now Oversold (VBLT)
www.thestreet.com - July 14 at 4:52 PM
americanbankingnews.com logo-$0.17 EPS Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter
www.americanbankingnews.com - July 13 at 7:54 AM
americanbankingnews.com logoVascular Biogenics Ltd. (VBLT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 4:58 PM
seekingalpha.com logoVascular Biogenics: An Under-The-Radar Oncology Play Near $6 - Seeking Alpha
seekingalpha.com - May 26 at 8:19 AM
seekingalpha.com logoVascular Biogenics' (VBLT) CEO, Dror Harats on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 29 at 10:50 AM
biz.yahoo.com logoQ4 2016 Vascular Biogenics Ltd Earnings Release - Before Market Open
us.rd.yahoo.com - March 27 at 8:25 AM
us.rd.yahoo.com logoVBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 27 at 8:25 AM
biz.yahoo.com logoVascular Biogenics Ltd Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 27 at 8:25 AM
investopedia.com logoVBL's Thyroid Cancer Drug Clears Phase 2 (VBLT)
www.investopedia.com - February 22 at 10:46 AM
us.rd.yahoo.com logoVBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer
us.rd.yahoo.com - February 22 at 10:46 AM
investopedia.com logoVBL Therapeutics Thyroid Cancer Drug Clears Phase 2
www.investopedia.com - February 22 at 10:46 AM
streetinsider.com logoPiper Jaffray Reiterates Overweight Rating and $11 PT on Vascular Biogenics (VBLT); Phase 2a Thyroid Cancer Drug ... - StreetInsider.com
www.streetinsider.com - February 21 at 4:25 PM
us.rd.yahoo.com logoVBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target
us.rd.yahoo.com - February 1 at 7:17 AM
us.rd.yahoo.com logoVBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
us.rd.yahoo.com - December 5 at 8:24 AM
us.rd.yahoo.com logo7:02 am Vascular Biogenics announces that the independent DSMC recommended that the Phase 3 GLOBE study investigating ofranergene obadenovec in recurrent glioblastoma study continue as planned
us.rd.yahoo.com - December 5 at 8:24 AM
streetinsider.com logoVBL Therapeutics (VBLT) Reports $20M at the Market Offering of Ordinary Shares
www.streetinsider.com - December 2 at 10:26 AM
streetinsider.com logoRoth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data
www.streetinsider.com - November 29 at 4:01 PM
streetinsider.com logoRoth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data
www.streetinsider.com - November 29 at 4:01 PM
nasdaq.com logoPre-Market Most Active for Nov 29, 2016 : MT, VALE, ASML, BAC, PBR, CHK, FCX, FOLD, NVLS, ARIA, AAPL, VBLT - Nasdaq
www.nasdaq.com - November 29 at 12:40 PM

Social

Chart

Vascular Biogenics (VBLT) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.